Cargando…
Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein highly expressed by prostate cancer cells. PSMA-based radioligand therapy (RLT) emerged as a promising therapeutic option for prostate cancer in the early 2000s, and has been clinically validated with great enthusiasm during t...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Singapore
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680309/ https://www.ncbi.nlm.nih.gov/pubmed/33175360 http://dx.doi.org/10.1007/s12149-020-01549-5 |